Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation.
The Journal of allergy and clinical immunology(2018)
摘要
HAE results in swelling due to KKS dysregulation and bradykinin production. FXII initiates the KKS and we have developed a human antibody that potently inhibits FXII protease activity as a novel prophylactic therapy for HAE.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要